FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954295954> ?p ?o ?g. }

• W2954295954 abstract "Background: YS-ON-001 is a complex containing synthetic double-strand RNA, a toll-like receptor 3 (TLR3) agonist. TLR3 agonist stimulates antigen-presenting cells, increases T, NK, NKT cells and decreases regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs), reprogrames macrophages from protumorigenic to anti-tumor. YS-ON-001 is being evaluated for systemic and intratumoral use alone or combined with checkpoint inhibitor to treat cancer. Method: The anti-tumor efficacy of systemically or intratumorally ( it ) injected YS-ON-001 alone or in combination with PD-1 antagonist was assessed in several syngeneic tumor models including pancreatic cancer, hepatocellular carcinoma. Tumors were implanted into left and/or right flanks while only one tumor was injected with YS-ON-001. YS-ON-001 was administered by IM injection every other day or it injection twice a week. Murine PD-1 antibody was infused intraperitoneally ( ip ) once a week. In addition to body weight, tumor volume was monitored on both flanks. Surviving mice with unnoticeable tumor were rechallenged. Flow cytometry was used to analyze immune cells from the tumors including T, NK, NKT cells, macrophages 1 and 2, Tregs, and MDSCs. Results: Within tumor microenvironment YS-ON-001 IM monotherapy resulted in increased infiltration of CD4+ T cells and CD8+ T cells, NK cells and NKT cells, reduced Tregs and MDSCs, and increased the M1/M2 ratio, leading to significant tumor growth inhibition in more than 10 cancer models. Combination of YS-ON-001 im with anti-PD1 ip resulted in greater anti-tumor efficacy compared to anti-PD1 monotherapy in both 4T1 breast cancer and LLC2 lung cancer models. Rejecting tumor rechallenge in surviving mice from the initial challenge treated with IM YS-ON-001suggested long-term anti-tumor immunity. Monotherapy of YS-ON-001 it or anti-PD-1 ip significantly suppresses tumor growth not only at the primary injection site, but also at uninjected site (p it with anti-PD-1 ip significantly enhanced suppressive effect of anti-PD1 at both primary injected and distant uninjected sites. Conclusions: these experiments demonstrated systemic or intratumoral delivery of YS-ON-001 can modulates immune responses in tumor microenvironment by increasing anti-tumor cells in T, NK, NKt cells and decreasing pro-tumor cells in Treg, MDSC, leading to significant tumor growth inhibition. Combination of YS-on-001, IM or It with PD-1 antibodies significantly enhanced the anti-tumor efficacy of PD-1 antibodies. These results provide a strong rationale and support clinical development as standalone therapy or in combination with other modalities such checkpoint inhibitors. Citation Format: Zhongkai Shi, Yuan Liu, Yi Zhang. Anti-cancer efficacy of systemic and Intratumoral YS-ON-001 as monotherapy or in combination with checkpoint inhibitor in syngeneic cancer models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4130." @default.
• W2954295954 created "2019-07-12" @default.
• W2954295954 creator A5024794344 @default.
• W2954295954 creator A5044544424 @default.
• W2954295954 creator A5046214153 @default.
• W2954295954 date "2019-07-01" @default.
• W2954295954 modified "2023-09-27" @default.
• W2954295954 title "Abstract 4130: Anti-cancer efficacy of systemic and Intratumoral YS-ON-001 as monotherapy or in combination with checkpoint inhibitor in syngeneic cancer models" @default.
• W2954295954 doi "https://doi.org/10.1158/1538-7445.sabcs18-4130" @default.
• W2954295954 hasPublicationYear "2019" @default.
• W2954295954 type Work @default.
• W2954295954 sameAs 2954295954 @default.
• W2954295954 citedByCount "0" @default.
• W2954295954 crossrefType "proceedings-article" @default.
• W2954295954 hasAuthorship W2954295954A5024794344 @default.
• W2954295954 hasAuthorship W2954295954A5044544424 @default.
• W2954295954 hasAuthorship W2954295954A5046214153 @default.
• W2954295954 hasConcept C121608353 @default.
• W2954295954 hasConcept C126322002 @default.
• W2954295954 hasConcept C139563560 @default.
• W2954295954 hasConcept C154317977 @default.
• W2954295954 hasConcept C167672396 @default.
• W2954295954 hasConcept C179185449 @default.
• W2954295954 hasConcept C185592680 @default.
• W2954295954 hasConcept C202751555 @default.
• W2954295954 hasConcept C203014093 @default.
• W2954295954 hasConcept C2776107976 @default.
• W2954295954 hasConcept C2777701055 @default.
• W2954295954 hasConcept C2780674031 @default.
• W2954295954 hasConcept C502942594 @default.
• W2954295954 hasConcept C55493867 @default.
• W2954295954 hasConcept C55721878 @default.
• W2954295954 hasConcept C71924100 @default.
• W2954295954 hasConcept C8891405 @default.
• W2954295954 hasConceptScore W2954295954C121608353 @default.
• W2954295954 hasConceptScore W2954295954C126322002 @default.
• W2954295954 hasConceptScore W2954295954C139563560 @default.
• W2954295954 hasConceptScore W2954295954C154317977 @default.
• W2954295954 hasConceptScore W2954295954C167672396 @default.
• W2954295954 hasConceptScore W2954295954C179185449 @default.
• W2954295954 hasConceptScore W2954295954C185592680 @default.
• W2954295954 hasConceptScore W2954295954C202751555 @default.
• W2954295954 hasConceptScore W2954295954C203014093 @default.
• W2954295954 hasConceptScore W2954295954C2776107976 @default.
• W2954295954 hasConceptScore W2954295954C2777701055 @default.
• W2954295954 hasConceptScore W2954295954C2780674031 @default.
• W2954295954 hasConceptScore W2954295954C502942594 @default.
• W2954295954 hasConceptScore W2954295954C55493867 @default.
• W2954295954 hasConceptScore W2954295954C55721878 @default.
• W2954295954 hasConceptScore W2954295954C71924100 @default.
• W2954295954 hasConceptScore W2954295954C8891405 @default.
• W2954295954 hasLocation W29542959541 @default.
• W2954295954 hasOpenAccess W2954295954 @default.
• W2954295954 hasPrimaryLocation W29542959541 @default.
• W2954295954 hasRelatedWork W2090475773 @default.
• W2954295954 hasRelatedWork W2403055543 @default.
• W2954295954 hasRelatedWork W2476540671 @default.
• W2954295954 hasRelatedWork W2476562928 @default.
• W2954295954 hasRelatedWork W2476999556 @default.
• W2954295954 hasRelatedWork W2481519667 @default.
• W2954295954 hasRelatedWork W2496937664 @default.
• W2954295954 hasRelatedWork W2506571864 @default.
• W2954295954 hasRelatedWork W2537973974 @default.
• W2954295954 hasRelatedWork W2564971483 @default.
• W2954295954 hasRelatedWork W2741492164 @default.
• W2954295954 hasRelatedWork W2885147819 @default.
• W2954295954 hasRelatedWork W2982372328 @default.
• W2954295954 hasRelatedWork W2992249467 @default.
• W2954295954 hasRelatedWork W2995913782 @default.
• W2954295954 hasRelatedWork W3081641895 @default.
• W2954295954 hasRelatedWork W3082482509 @default.
• W2954295954 hasRelatedWork W3082914954 @default.
• W2954295954 hasRelatedWork W3180806010 @default.
• W2954295954 hasRelatedWork W3182464748 @default.
• W2954295954 isParatext "false" @default.
• W2954295954 isRetracted "false" @default.
• W2954295954 magId "2954295954" @default.
• W2954295954 workType "article" @default.